D&D Pharmatech Competitors or Alternatives

D&D Pharmatech's top competitors include ILIAS, LISCure and Blade Therapeutics.

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

D&D Pharmatech's company profile

Yoo-Seok Hong

CEO

90/100
0
$206.9M
$ < 1M
1
D&D Pharmatech's Competitor - ILIAS logo

Chulhee Choi

President & CEO

90/100
1 - 25
$39.1M
$100K - 5M
2
D&D Pharmatech's Competitor - LISCure logo

Hwaseop Chin

CEO

90/100
1 - 25
$27.8M
$100K - 5M
3
D&D Pharmatech's Competitor - Blade Therapeutics logo

Wendye Robbins

President & CEO

97/100
25 - 100
$95M
$5M - 25M
4
D&D Pharmatech's Competitor - Dawon Medax logo

Park Sun-soon

CEO

90/100
25 - 100
- -
5
D&D Pharmatech's Competitor - Oblique Therapeutics logo

Christer Nordstedt

CEO

- -
$5M
$100K - 5M

D&D Pharmatech VS ILIAS

ILIAS is D&D Pharmatech's #1 competitor. ILIAS's headquarters is in Daejeon, Daejeon Gwang'yeogsi, and was founded in 2015. Like D&D Pharmatech, ILIAS also works within the Biotechnology sector. ILIAS generates ∞% of D&D Pharmatech's revenue.

D&D Pharmatech VS LISCure

LISCure is one of D&D Pharmatech's top rivals. LISCure was founded in Seongnam, Gyeonggido} in 2018. LISCure operates in the Biotechnology industry. Compared to D&D Pharmatech, LISCure generates $4.5M more revenue.

D&D Pharmatech VS Blade Therapeutics

Blade Therapeutics is one of D&D Pharmatech's top competitors. Blade Therapeutics is a Private company that was founded in 2015 in South San Francisco, California. Blade Therapeutics is in the Biotechnology industry. Compared to D&D Pharmatech, Blade Therapeutics has 25 more employees.

Frequently Asked Questions about D&D Pharmatech

  1. Who are D&D Pharmatech's top competitors?

    D&D Pharmatech's top 3 competitors are ILIAS, LISCure, Blade Therapeutics.
  2. Who is similar to D&D Pharmatech?

    ILIAS is the most similar to D&D Pharmatech. LISCure and Blade Therapeutics are also similar to D&D Pharmatech.
  1. Are D&D Pharmatech and ILIAS competitors?

    Yes, ILIAS is one of D&D Pharmatech’s top competitors.